Drug Profile
Barasertib
Alternative Names: AZD-1152Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Acetamides; Antineoplastics; Fluorobenzenes; Pyrazoles; Quinazolines
- Mechanism of Action Aurora kinase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Solid tumours
Most Recent Events
- 01 Mar 2017 AstraZeneca completes a phase I trial for Solid tumours (Late-stage disease) in USA (IV) (NCT00338182)
- 31 Dec 2011 Discontinued - Phase-I/II for Acute myeloid leukaemia in USA and European Union (IV)
- 31 Dec 2011 Discontinued - Phase-II for Acute myeloid leukaemia in USA, European Union, Japan and Australia (IV)